

James E Wooldridge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7152812/publications.pdf>

Version: 2024-02-01

31
papers

2,104
citations

394390

19
h-index

434170

31
g-index

31
all docs

31
docs citations

31
times ranked

2744
citing authors

#	ARTICLE	IF	CITATIONS
1	Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. <i>Cancer Discovery</i> , 2021, 11, 2998-3007.	9.4	80
2	Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. <i>British Journal of Haematology</i> , 2017, 176, 783-795.	2.5	39
3	A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1910-1919.	7.0	66
4	Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016, 22, 5688-5695.	7.0	18
5	Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma. <i>Journal of Medical Economics</i> , 2016, 19, 477-486.	2.1	22
6	Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity Fcγ3R11a Patients with Previously Treated Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 42-48.	1.3	29
7	A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2013-2017.	1.3	15
8	A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2012, 18, 5043-5050.	7.0	26
9	Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fcγ3R11a-Genotyped Patients with Previously Treated Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 1395-1403.	7.0	61
10	Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 211-217.	1.3	82
11	Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 2097-2104.	1.3	9
12	Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. <i>Cancer Science</i> , 2011, 102, 432-438.	3.9	25
13	A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2011, 86, 573-578.	4.1	21
14	Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. <i>Epigenomics</i> , 2009, 1, 39-61.	2.1	57
15	Can a positive positron emission tomography scan be positive news?. <i>Leukemia and Lymphoma</i> , 2007, 48, 227-228.	1.3	2
16	Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. <i>Carcinogenesis</i> , 2007, 28, 60-70.	2.8	83
17	Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. <i>Leukemia and Lymphoma</i> , 2006, 47, 657-663.	1.3	16
18	B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. <i>Blood</i> , 2006, 108, 2712-2719.	1.4	130

#	ARTICLE	IF	CITATIONS
19	Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. <i>Blood</i> , 2006, 108, 2648-2654.	1.4	215
20	Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. <i>Journal of Immunotherapy</i> , 2006, 29, 558-568.	2.4	145
21	Primary Cardiac Non-Hodgkin's Lymphoma Diagnosed by Transthoracic Echocardiography. <i>Echocardiography</i> , 2006, 23, 147-148.	0.9	6
22	Serum Alters the Uptake and Biologic Activity of CpG Oligodeoxynucleotides in B Cell Chronic Lymphocytic Leukemia. <i>Oligonucleotides</i> , 2005, 15, 51-59.	2.7	2
23	Improved Survival of Follicular Lymphoma Patients in the United States. <i>Journal of Clinical Oncology</i> , 2005, 23, 5019-5026.	1.6	249
24	Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2005, 23, 4652-4661.	1.6	364
25	Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. <i>Journal of Leukocyte Biology</i> , 2005, 77, 378-387.	3.3	90
26	Optic neuropathy due to anaplastic large cell lymphoma. <i>Seminars in Ophthalmology</i> , 2004, 19, 81-87.	1.6	7
27	Introduction: Post-treatment surveillance for potentially curable malignancies. <i>Seminars in Oncology</i> , 2003, 30, 337.	2.2	6
28	Post-treatment surveillance of patients with lymphoma treated with curative intent. <i>Seminars in Oncology</i> , 2003, 30, 375-381.	2.2	7
29	CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. <i>Current Opinion in Oncology</i> , 2003, 15, 440-445.	2.4	45
30	Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma. <i>Blood</i> , 1997, 89, 2994-2998.	1.4	184
31	T-cell activation induced by anti-CD3 + anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand. <i>Cancer Immunology, Immunotherapy</i> , 1997, 45, 174-179.	4.2	3